|
1
|
Neelam K, Cheung CM, Ohno-Matsui K, Lai TY
and Wong TY: Choroidal neovascularization in pathological myopia.
Prog Retin Eye Res. 31:495–525. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wong TY, Ferreira A, Hughes R, Carter G
and Mitchell P: Epidemiology and disease burden of pathologic
myopia and myopic choroidal neovascularization: An evidence-based
systematic review. Am J Ophthalmol. 157:9–25.e12. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ohno-Matsui K, Yoshida T, Futagami S,
Yasuzumi K, Shimada N, Kojima A, Tokoro T and Mochizuki M: Patchy
atrophy and lacquer cracks predispose to the development of
choroidal neovascularization in pathological myopia. Br J
Ophthalmol. 87:570–573. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wakabayashi T and Ikuno Y: Choroidal
filling delay in choroidal neovascularization due to pathological
myopia. Br J Ophthalmol. 94:611–15. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ikuno Y, Jo Y, Hamasaki T and Tano Y:
Ocular risk factors for choroidal neovascularization in pathologic
myopia. Invest Ophthalmol Vis Sci. 51:3721–3725. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Grossniklaus HE and Green WR: Pathologic
findings in pathologic myopia. Retina. 12:127–133. 1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Toto L, Di Antonio L, Costantino O and
Mastropasqua R: Anti-VEGF therapy in myopic CNV. Curr Drug Targets.
22:1054–1063. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ehrlich R, Kramer M, Rosenblatt I,
Weinberger D, Mimouni K, Priel E and Axer-Siegel R: Photodynamic
therapy for choroidal neovascularization in young adult patients.
Int Ophthalmol. 30:345–351. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sickenberg M, Schmidt-Erfurth U, Miller
JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H,
Barbazetto I, Gragoudas ES, et al: A preliminary study of
photodynamic therapy using verteporfin for choroidal
neovascularization in pathologic myopia, ocular histoplasmosis
syndrome, angioid streaks and idiopathic causes. Arch Ophthalmol.
118:327–336. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cohen SY: Anti-VEGF drugs as the 2009
first-line therapy for choroidal neovascularization in pathologic
myopia. Retina. 29:1062–1066. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Teo KY, Ng WY, Lee SY and Cheung CM:
Management of myopic choroidal neovascularization: Focus on
anti-VEGF therapy. Drugs. 76:1119–1133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ferrara N, Damico L, Shams N, Lowman H and
Kim R: Development of ranibizumab, an anti-vascular endothelial
growth factor antigen binding fragment, as therapy for neovascular
age-related macular degeneration. Retina. 26:859–870.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Laud K, Spaide RF, Freund KB, Slakter J
and Klancnik JM Jr: Treatment of choroidal neovascularization in
pathologic myopia with intravitreal bevacizumab. Retina.
26:960–963. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Howaidy A and Eldaly ZH: Comparison of
structural and functional outcome of aflibercept versus ranibizumab
in patients with myopic choroidal neovascularization. Eur J
Ophthalmol. 31:211–217. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wu Z, Zhou P, Li X, Wang H, Luo D, Qiao H,
Ke X and Huang J: Structural characterization of a recombinant
fusion protein by instrumental analysis and molecular modeling.
PLoS One. 8(e57642)2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ikuno Y, Ohno-Matsui K, Wong TY,
Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O,
Ishibashi T and MYRROR Investigators: Intravitreal aflibercept
injection in patients with myopic choroidal neovascularization: The
MYRROR study. Ophthalmology. 122:1220–1227. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Karasu B and Celebi ARC: The efficacy of
different anti-vascular endothelial growth factor agents and
prognostic biomarkers in monitoring of the treatment for myopic
choroidal neovascularization. Int Ophthalmol. 42:2729–2740.
2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Broadhead GK, Keenan TDL, Chew EY, Wiley
HE and Cukras CA: Comparison of agents using higher dose anti-VEGF
therapy for treatment-resistant neovascular age-related macular
degeneration. Graefes Arch Clin Exp Ophthalmol. 260:2239–2247.
2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
You QS, Gaber R, Meshi A, Ramkumar HL,
Alam M, Muftuoglu IK and Freeman WR: High-dose high-frequency
aflibercept for recalcitrant neovascular age-related macular
degeneration. Retina. 38:1156–1165. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nguyen QD, Campochiaro PA, Shah SM,
Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK,
Slakter J, Haller JA, et al: Evaluation of very high-and very
low-dose intravitreal aflibercept in patients with neovascular
age-related macular degeneration. J Ocul Pharmacol Ther.
28:581–588. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pece A and Milani P: Intravitreal
aflibercept for myopic choroidal neovascularization. Graefes Arch
Clin Exp Ophthalmol. 254:2327–2332. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bruè C, Pazzaglia A, Mariotti C, Reibaldi
M and Giovannini A: Aflibercept as primary treatment for myopic
choroidal neovascularisation: A retrospective study. Eye (Lond).
30:139–145. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Korol AR, Zadorozhnyy OS, Naumenko VO,
Kustryn TB and Pasyechnikova NV: Intravitreal aflibercept for the
treatment of choroidal neovascularization associated with
pathologic myopia: A pilot study. Clin Ophthalmol. 10:2223–2229.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fauser S and Muether PS: Clinical
correlation to differences in ranibizumab and aflibercept vascular
endothelial growth factor suppression times. Br J Ophthalmol.
100:1494–1498. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen SL, Tang PL and Wu TT: Result of
intravitreal aflibercept injection for myopic choroidal
neovascularization. BMC Ophthalmol. 21(342)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kung YH, Wu TT and Huang YH: One-year
outcome of two different initial dosing regimens of intravitreal
ranibizumab for myopic choroidal neovascularization. Acta
Ophthalmol. 92:e615–e620. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Korol A, Kustryn T, Zadorozhnyy O,
Pasyechnikova N and Kozak I: Comparison of efficacy of intravitreal
ranibizumab and aflibercept in eyes with myopic choroidal
neovascularization: 24-month follow-up. J Ocul Pharmacol Ther.
36:122–125. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhu W, Hao Y, Yuan Z, Huang C, Liu J and
Ma Y: Long-term outcomes of high-dose conbercept treatment for
myopic cho-roidal neovascularisation and idiopathic choroidal
neovascularisation. Ophthalmic Res, Feb 6, 2023 (Epub ahead of
print).
|
|
29
|
Wang JK, Huang TL, Chang PY, Chen YT,
Chang CW, Chen FT, Hsu YR and Chen YJ: Intravitreal aflibercept
versus bevacizumab for treatment of myopic choroidal
neovascularization. Sci Rep. 8(14389)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Corazza P, Kabbani J, Soomro T, Alam MMR,
D'Alterio FM and Younis S: Three-year real-world outcomes of
intravitreal anti-VEGF therapies in patients affected by myopic
choroidal neovascularization. Eur J Ophthalmol. 31:2481–2487.
2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fung AE, Rosenfeld PJ and Reichel E: The
international intravitreal bevacizumab safety survey: Using the
internet to assess drug safety worldwide. Br J Ophthalmol.
90:1344–1349. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Solomon SD, Lindsley KB, Krzystolik MG,
Vedula SS and Hawkins BS: Intravitreal bevacizumab versus
ranibizumab for treatment of neovascular age-related macular
degeneration: Findings from a cochrane systematic review.
Ophthalmology. 123:70–77. 2016.PubMed/NCBI View Article : Google Scholar
|
